Arokaris (fosnetupitant) / Helsinn, Otsuka - LARVOL DELTA

Extended physicochemical stability of ready-to-administer fosnetupitant/palonosetron infusion solutions and admixtures with dexamethasone injection. (PubMed, Eur J Hosp Pharm) - "Reconstituted FNET/PAL (Akynzeo) infusion solutions and FNET/PAL/DEX admixtures diluted with 30 mL and 100 mL NS in prefilled PO bags are physicochemically stable for at least 5 days (subvisible particle count specification fulfilled) and 28 days (subvisible particle count not tested) when stored light-protected at 25°C. Results allow pharmacy-based preparation of RTA FNET/PAL and RTA FNET/PAL/DEX infusion solutions in advance."

Journal • Oncology

Our experience with the use of Trastuzma budeluxtecan at our hospital (JBCS 2026) - "Introduction) Trastuzumab deruxtecan (hereinafter referred to as T-DXd) has been proven effective not only in HER2-positive breast cancer but also in cases with low and very low HER2 expression, and is currently being used in many cases, demonstrating its efficacy...All HER23+ cases had received trastuzumab/pertuzumab as prior treatment...Nausea as a side effect is well controlled at our hospital using fosnetupitant. We have not yet experienced cases of very low HER2 expression at our hospital, but we expect to have more opportunities to use it in the future and are looking forward to its therapeutic effect."

Clinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Solid Tumor • ERBB3 • HER-2

A Review of Trastuzumab Deruxtecan Use at Our Hospital : Considering Adverse Events such as Nausea and Vomiting. (JBCS 2026) - "A significant correlation was observed between 27% (P=0.0145) of patients with a history of alcohol consumption (13 cases, 59%) and 9 cases without (41%) (P=0.0451), but no differences were found in age, number of regimens, presence or absence of initial fosnetupitant, or HER2 expression. We believe this was influenced by the inclusion of late-line use in this study, and especially by the high number of Tntype cases in the HER2 low-expression group. To obtain the effects of T-DXd while maintaining QOL, appropriate dose reduction or antiemetic therapy is necessary in patients who appear to be at high risk of nausea and vomiting."

Adverse events • Clinical • Review • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases • Solid Tumor • Triple Negative Breast Cancer • HER-2

MULTICENTER PROSPECTIVE STUDY OF FOSNETUPITANT-BASED ANTIEMETIC THERAPY AND CINV RISK FACTORS IN UPPER GASTROINTESTINAL CANCER (CCOG2301) (MASCC-ISOO 2026) - "Patients with upper GI cancer received either highly emetogenic chemotherapy (HEC; cisplatin-based) or moderately emetogenic chemotherapy (MEC; oxaliplatin-based) were enrolled. All patients were treated with fosnetupitant, palonosetron, and dexamethasone...Conclusions Fosnetupitant-based triplet therapy met the predefined primary endpoint, but delayed-phase CINV remained common with different peak timings between HEC and MEC. Cancer cachexia independently increased CINV risk, emphasizing the importance of risk-aware management in routine practice."

CINV • Clinical • Cachexia • Chemotherapy-Induced Nausea and Vomiting • Gastrointestinal Cancer • Oncology • Solid Tumor

EFFICACY OF FOSNETUPITANT FOR LONG-DELAYED CINV IN OXALIPLATIN-BASED CHEMOTHERAPY: PROSPECTIVE STUDY (MASCC-ISOO 2026) - "Introduction The efficacy of fosnetupitant (FosNTP) combined with palonosetron and dexamethasone for preventing highly emetogenic chemotherapy–induced nausea and vomiting (CINV) has been demonstrated in the phase III CONSOLE study. Conclusions The FosNTP-containing triplet regimen showed favorable long-delayed antiemetic efficacy in patients receiving oxaliplatin-based chemotherapy. Nonetheless, those with high emetogenic risk factors may require additional supportive strategies."

CINV • Clinical • Chemotherapy-Induced Nausea and Vomiting

Steroid sparing regimen with inj palonosetron–fosnetupitant (Akynzeo) for CINV in patients receiving ≥2 chemotherapy cycles: An observational study (MASCC-ISOO 2026) - "All patients received oral ondansetron for three days post-chemotherapy. These findings suggest that routine dexamethasone may be avoidable in selected patients, including those with diabetes, without adversely affecting CINV outcomes or quality of life. Larger, controlled studies are warranted to confirm these results."

CINV • Clinical • Observational data • Chemotherapy-Induced Nausea and Vomiting • Diabetes • Metabolic Disorders

Comparative Efficacy of Fosnetupitant and Fosaprepitant for Delayed Vomiting in Patients Receiving Irinotecan-Oxaliplatin Combination Chemotherapy: A Retrospective Propensity Score-Matched Study. (PubMed, Cancer Manag Res) - "With fosnetupitant, the time to first vomiting was longer (3/68 vs. 11/68, hazard ratio: 0.20, p=0.045), injection site reactions were fewer (0.0% vs. 19.1%, p0.05). Despite the retrospective design, possible calendar-time confounding, and limited number of events, our results suggest that fosnetupitant offers better control of long-delayed and overall vomiting and a favorable safety profile, compared with fosaprepitant, in patients receiving FOLFIRINOX/FOLFOXIRI regimens."

Journal • Retrospective data • Chemotherapy-Induced Nausea and Vomiting • Constipation • Gastroenterology • Gastrointestinal Disorder

Fosnetupitant for long-delayed chemotherapy-induced nausea and vomiting in oxaliplatin-based regimens: a prospective observational study (LODEC-N). (PubMed, Cancer Chemother Pharmacol) - "The triplet regimen involving FosNTP showed promising results and potential utility for managing long-delayed CINV in patients receiving oxaliplatin-based chemotherapy. However, given the single-arm study design, further comparative trials are warranted to confirm these findings. Participants with high emetic risk factors-such as younger age, female sex, or a history of motion sickness-continued to experience suboptimal control. TRIAL REGISTRATION NUMBER AND DATE OF REGISTRATION: jRCT1030230130."

CINV • Journal • Observational data • Chemotherapy-Induced Nausea and Vomiting

The impact of NK1 receptor antagonist selection on chemotherapy-related adverse events: a retrospective study of adverse events in paclitaxel or nab-paclitaxel and carboplatin combination therapy with fosnetupitant and aprepitant use. (PubMed, Front Pharmacol) - "Conversely, among nab-PTX users, 10/49 patients in the FosNTP group and 8/53 patients in the APR group developed grade ≥3 neutropenia, with no significant difference observed (20.4% vs. 17.0%; p = 0.182). This study suggests that the use of FosNTP in PTX-containing regimens may lead to a higher incidence of grade ≥3 neutropenia compared to APR, emphasizing the importance of vigilant monitoring throughout the treatment period."

Adverse events • Journal • Retrospective data • Hematological Disorders • Lung Cancer • Neutropenia • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Fosnetupitant Versus Fosaprepitant for Delayed Vomiting Upon Irinotecan-Oxaliplatin Combination Chemotherapy for Pancreatic/Colorectal Cancer. (PubMed, Anticancer Res) - "The effectiveness of fosnetupitant may vary according to cancer type, suggesting the need to tailor antiemetic strategies for patients receiving irinotecan-oxaliplatin combination chemotherapy."

Clinical • Journal • Retrospective data • Chemotherapy-Induced Nausea and Vomiting • Colorectal Cancer • Oncology • Pancreatic Cancer • Solid Tumor

Effectiveness of Adding Fosnetupitant to a Doublet Antiemetic Therapy Containing Palonosetron for Trastuzumab Deruxtecan-Induced Nausea and Vomiting - A Retrospective Comparative Study (PubMed, Gan To Kagaku Ryoho) - "Adding fosnetupitant increased the complete antiemetic control rate in the PDN group by 34.9% compared with that in the PD group. Triplet antiemetic therapy with palonosetron, dexamethasone, and fosnetupitant may provide effective antiemetic prophylaxis for T-DXd-induced nausea and vo miting."

Clinical • Journal • Retrospective data

Effective Use of Olanzapine for Chemotherapy-Induced Nausea and Vomiting in a Patient Receiving Dose-Adjusted Rituximab, Etoposide, Prednisone, Vincristine (Oncovin®), Cyclophosphamide, and Doxorubicin (R-EPOCH): A Case Report. (PubMed, Cureus) - "The patient received prophylactic antiemetic therapy with olanzapine (5 mg after dinner for six days), palonosetron, and fosnetupitant during DA-R-EPOCH therapy. A four-drug antiemetic regimen, including olanzapine, supported the feasibility of preventing CINV in this case involving DA-R-EPOCH therapy. However, adverse events potentially related to olanzapine were observed, suggesting the need for further investigation into its optimal dosage."

CINV • Journal • B Cell Lymphoma • Chemotherapy-Induced Nausea and Vomiting • Constipation • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma

Optimizing Antiemetic Support in Anthracycline-Based Chemotherapy for Early Breast Cancer: Protocol for a Prospective Observational Study of Four-Drug Antiemetic Therapy Including Fosnetupitant and Olanzapine. (PubMed, JMIR Res Protoc) - "Four-drug antiemetic therapy, consisting of a neurokinin-1 receptor antagonist (NK1RA), a 5-hydroxytryptamine type 3 receptor antagonist (5-HT3RA), dexamethasone (DEX), and olanzapine (OLZ), is currently recommended for HEC. Data collection is expected to continue until April 2026, and both data collection and analyses are anticipated to be completed in 2027. This study will provide real-world evidence on the effectiveness and safety of a four-drug antiemetic regimen, including FosNTP and OLZ, in patients receiving anthracycline-based HEC and may inform optimal OLZ dosing strategies."

Clinical protocol • Journal • Observational data • Breast Cancer • Chemotherapy-Induced Nausea and Vomiting • Oncology • Solid Tumor

Exploratory Analysis of Nausea and Vomiting Probability over Multiple Cycles of NEPA (netupitant/palonosetron) Prophylaxis in Metastatic Breast Cancer Patients Treated withTrastuzumab Deruxtecan (SABCS 2025) - "Since MBC patients may receive T-DXd for an extended period, effective management of NV could help maintain dose intensity, reduce the risk of treatment discontinuation, and improve quality-of-life.Preventing NV can also contribute to reduce other adverse events, like fatigue Effective NV control from the first cycle with a NK1 receptor antagonist (RA)-based regimen is crucial for optimal management throughout subsequent cycles.This exploratory retrospective analysis examined the probability of patients experiencing NV over multiple cycles of T-DXd following antiemetic prophylaxis with NEPA, a fixed-combination of an NK1 RA (netupitant/fosnetupitant) and 5-HT3 RA (palonosetron).Occurrence and severity of NV in patients with HER2-positive or HER2-low MBC over the first 5 cycles of T-DXd for each patient were extracted and analyzed from clinical records at a single-center in Italy.Probability of NV occurring in each of 5 cycles of T-DXd was estimated using a logistic..."

Clinical • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Sustained antiemetic efficacy of fosnetupitant versus aprepitant in carboplatin-based chemotherapy: a retrospective observational study. (PubMed, Int J Clin Oncol) - "F-NTP demonstrated superior antiemetic efficacy to that of APR in CBDCA-based regimens, particularly maintaining higher CR rates through the acute and delayed phases. F-NTP was also well tolerated, supporting its potential as a strong prophylactic agent for preventing chemotherapy-induced nausea and vomiting."

Journal • Observational data • Retrospective data • Chemotherapy-Induced Nausea and Vomiting • Oncology

STOP-CINV Study: Safety and Efficacy of IV Akynzeo® (Fosnetupitant 235 mg and Palonosetron 0.25 mg) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Indian Patients. (PubMed, Cureus) - "Purpose IV Akynzeo® (IV fosnetupitant + palonosetron) is the first fixed IV combination designed to target key pathways of emesis, enabling convenient single-dose administration. The complete response rates with IV Akynzeo® were as follows: 84.27% (95% CI: 78.01-89.29) in the acute phase, 93.26% (95% CI: 88.52-96.47) in the delayed phase, 96.07% (171 of 178 patients; 95% CI: 92.07-98.40) in the extended phase, 83.15% (95% CI: 76.82-88.33) in the overall phase, and 80.34% (143 of 178 patients; 95% CI: 73.73-85.91) in the extended overall phase. Conclusions IV Akynzeo® was well tolerated and demonstrated substantial effectiveness in mitigating CINV in patients undergoing HEC/MEC across the acute, delayed, and extended phases."

CINV • Journal • Chemotherapy-Induced Nausea and Vomiting • Fatigue • Pain

Breast Cancer‒Associated Allergy Caused by Fosnetupitant-A Report of Four Cases (PubMed, Gan To Kagaku Ryoho) - "We describe the cases of 4 patients with breast cancer who developed an allergy to fosnetupitant (Pro‒NETU). The patients in cases 2, 3, and 4 had known allergies to docetaxel, and the cause of allergy in case 4 was unknown. Polysorbate 80, contained in docetaxel, fosaprepitant, and Pro‒NETU, was suspected to be the cause of allergy in cases 1, 2, and 3."

Journal • Allergy • Breast Cancer • Cardiovascular • Immunology • Oncology • Pulmonary Disease • Solid Tumor

Individual patient data meta-analysis of NEPA versus aprepitant-based antiemetic regimens for preventing chemotherapy-induced nausea and vomiting. (PubMed, Future Oncol) - "This individual patient data (IPD) meta-analysis compared the efficacy of NEPA (netupitant/fosnetupitant) and aprepitant/fosaprepitant-based regimens in preventing chemotherapy-induced nausea and vomiting (CINV)...A total of six studies involving 2,767 patients were included evaluating NEPA plus dexamethasone versus aprepitant/fosaprepitant plus any 5-HT3RA plus dexamethasone for patients with cancer receiving HEC/MEC. Complete response and no significant nausea rates were similar during the acute (0-24 h) phase but NEPA showed significantly higher rates than aprepitant during the delayed ( > 24-120 h) and overall (0-120 h) phases and on Days 3-5 following chemotherapy. Improved CINV prevention was observed with NEPA-based regimens, particularly during Days 3-5, highlighting its potential for managing prolonged nausea and vomiting associated with emerging anticancer targeted therapies."

CINV • Journal • Retrospective data • Review • Chemotherapy-Induced Nausea and Vomiting • Oncology

EXPLORATORY ANALYSIS OF THE ASSOCIATION BETWEEN NAUSEA, VOMITING, AND FATIGUE IN METASTATIC BREAST CANCER PATIENTS TREATED WITH TRASTUZUMAB DERUXTECAN (MASCC-ISOO 2025) - "All but 1 patient received antiemetic prophylaxis from first cycle; most received NEPA, a fixed-combination of an NK1RA (netupitant/fosnetupitant) and 5-HT3RA (palonosetron), with dexamethasone. Conclusions These exploratory findings suggest a potential link between prior NV and fatigue, indicating that controlling NV may help manage fatigue in MBC patients receiving T-DXd. More data are needed to confirm."

Clinical • Metastases • Breast Cancer • Fatigue • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Design of a single-institution prospective observational study to evaluate the efficacy and tolerability of four-drug antiemetic therapy for anthracycline-based chemotherapy for early breast cancer (SG-BCC 2025) - "Goals: The aim is to present our study design to evaluate the efficacy, tolerability of the co-administration of 4 drugs {fosnetupitant (FosNTP), palonosetron (PALO), dexamethasone (DEX) and olanzapine (OLZ)} to prevent chemotherapy-induced nausea and vomiting (CINV) in early breast cancer (EBC) patients (pts) treated with anthracycline-based (neo)adjuvant chemotherapy {(N)ACT}. For prophylaxis of CINV induced by highly emetogenic chemotherapy, several guidelines recommend the multiple use of targeted prophylactic drugs including neurokinin 1 receptor-antagonists (RA), 5-hydroxytryptamine-3 RA in combination with DEX, and OLZ. However, despite OLZ contribute to CINV prophylaxis owing to its antidopaminergic, antiserotonergic and anticholinergic properties, OLZ has some characteristic side effects such as somnolence that negatively impact the quality of life of EBC pts. The research question of our study is whether novel four-drug antiemetic therapy (FosNTP, PALO, DEX..."

Clinical • Observational data • Breast Cancer • Oncology • Solid Tumor

Safety and Feasibility of Outpatient Zolbetuximab Administration in Community Cancer Care: A Mixed-methods Analysis. (PubMed, In Vivo) - "Outpatient zolbetuximab administration proved safe and feasible in a community setting when implemented with appropriate protocols and support systems. This implementation model could serve as a template for delivering complex cancer therapies in resource-limited settings."

Journal • Gastric Cancer • Oncology • Solid Tumor • CLDN18

Cost-effectiveness analysis of Fosnetupitant, an NK1 Receptor Antagonist, Compared to Fosaprepitant and Aprepitant (JSMO 2025) - No abstract available

Cost effectiveness • HEOR • Oncology

A Clinical Trial to Assess Safety and Pharmacokinetics of Fosnetupitant 235 Mg and Metabolites in Healthy Volunteers (clinicaltrials.gov) - P1 | N=50 | Terminated | Sponsor: Helsinn Healthcare SA

New P1 trial

Cost-effectiveness analysis of fosnetupitant in patients receiving cisplatin in Japan: analysis based on real-world data. (PubMed, Support Care Cancer) - "F-NTP is more cost-effective than F-APR, but slightly less cost-effective than APR."

Clinical • HEOR • Journal • Real-world evidence • Chemotherapy-Induced Nausea and Vomiting

Safety of a short-term infusion of fosnetupitant in patients with gastrointestinal and breast cancer: a prospective study. (PubMed, Oncologist) - "Short-term infusion of fosnetupitant, administered over 15 minutes, was demonstrated to be safe and effective for patients receiving HEC or MEC (Japan Registry of Clinical Trials Trial ID: jRCT1041220144)."

Journal • Allergy • Breast Cancer • Chemotherapy-Induced Nausea and Vomiting • Gastrointestinal Disorder • Oncology • Solid Tumor